A fixed-dose combination nasal spray containing Xylometazoline Hydrochloride (a sympathomimetic alpha-adrenergic agonist) and Ipratropium Bromide (an anticholinergic/antimuscarinic agent). This combination provides rapid and prolonged symptomatic relief from rhinorrhea (runny nose) associated with allergic and non-allergic rhinitis and the common cold by targeting two distinct physiological pathways. Xylometazoline acts as a decongestant by vasoconstriction, while Ipratropium inhibits glandular secretions.
Adult: One spray (typically 0.05% Xylometazoline + 0.03% Ipratropium per spray) in each nostril, 2 to 3 times a day. Maximum: 3 times daily. Do not exceed 7-10 days of continuous use.
Note: 1. Shake the bottle gently. 2. Clear nasal passages by blowing nose gently. 3. Keep head upright, insert nozzle into nostril. 4. Close the other nostril with finger. 5. Breathe in gently through the nose while pressing down firmly on the pump to release spray. 6. Breathe out through mouth. 7. Repeat for other nostril. 8. Avoid deep inhalation (sniffing hard) to prevent medication from going into throat. 9. Clean nozzle weekly with warm water.
The combination exerts a dual mechanism: 1) Xylometazoline acts on alpha-1 and alpha-2 adrenergic receptors in the vascular smooth muscle of nasal mucosa, causing vasoconstriction, reduced blood flow, and decreased edema/turbinate swelling, leading to decongestion. 2) Ipratropium is a competitive antagonist of muscarinic (M3) receptors on nasal mucosal glands, inhibiting parasympathetically mediated secretions, thus reducing the volume of watery rhinorrhea.
Pregnancy: Category C (US FDA). Animal reproduction studies have shown adverse effects. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. Avoid especially in first trimester.
Driving: Generally safe. However, if blurred vision, dizziness, or drowsiness occurs, patients should not drive or operate machinery.
| Monoamine Oxidase Inhibitors (MAOIs) e.g., Phenelzine, Selegiline | Potentiates pressor effects of Xylometazoline, risk of severe hypertension. | Major |
| Tricyclic Antidepressants (TCAs) e.g., Amitriptyline | May potentiate pressor effects of Xylometazoline and anticholinergic effects of Ipratropium. | Moderate |
| Other Anticholinergic Drugs (e.g., Atropine, Oxybutynin, first-gen antihistamines) | Additive anticholinergic side effects (dry mouth, urinary retention, constipation, blurred vision). | Moderate |
| Beta-blockers (non-cardioselective) e.g., Propranolol | May potentiate pressor response to Xylometazoline, leading to hypertension and bradycardia. | Moderate |
| Other Sympathomimetics (e.g., Pseudoephedrine, Phenylephrine oral/ nasal) | Additive adrenergic effects, increasing risk of tachycardia and hypertension. | Moderate |
Same composition (Xylometazoline (NA) + Ipratropium (NA)), different brands: